Treatment failure in osteoporosis

被引：170

作者：

Diez-Perez, A. ^{[1
]}

Adachi, J. D. ^{[2
]}

Agnusdei, D. ^{[3
]}

Bilezikian, J. P. ^{[4
]}

Compston, J. E. ^{[5
]}

Cummings, S. R. ^{[6
]}

Eastell, R. ^{[7
]}

Eriksen, E. F. ^{[8
,9
]}

Gonzalez-Macias, J. ^{[10
]}

Liberman, U. A. ^{[11
]}

Wahl, D. A. ^{[12
]}

Seeman, E. ^{[13
]}

Kanis, J. A. ^{[14
]}

Cooper, C. ^{[15
,16
]}

机构：

[1] Autonomous Univ Barcelona, Dept Internal Med & Infect Dis, Hosp del Mar IMIM, RETICEF,Inst Carlos III, Barcelona 08003, Spain

[2] McMaster Univ, Dept Med, Div Rheumatol, Hamilton, ON, Canada

[3] Eli Lilly & Co, Florence, Italy

[4] Columbia Univ, Coll Phys & Surg, New York, NY USA

[5] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England

[6] Calif Pacific Med Ctr, San Fransisco Coordinating Ctr, Res Inst, San Francisco, CA USA

[7] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England

[8] Univ Oslo, Dept Endocrinol, Oslo Univ Hosp, Oslo, Norway

[9] Univ Oslo, Fac Med, Oslo, Norway

[10] Univ Cantabria, Dept Internal Med, Hosp Marques de Valdecilla IFIMAV, RETICEF, Santander, Spain

[11] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel

[12] Int Osteoporosis Fdn, Nyon, Switzerland

[13] Univ Melbourne, Endocrine Ctr, Austin Hlth, Melbourne, Vic, Australia

[14] Univ Sheffield, WHO Collaborating Ctr Metab Bone Dis, Sheffield, S Yorkshire, England

[15] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England

[16] Univ Oxford, NIHR Musculoskeletal Biomed Res Unit, Inst Musculoskeletal Sci, Oxford, England

来源：

OSTEOPOROSIS INTERNATIONAL | 2012年 / 23卷 / 12期

关键词：

Bone mineral density; Fractures; Markers of bone turnover; Osteoporosis; Treatment; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; NONVERTEBRAL FRACTURE; TURNOVER MARKERS; RISK; REDUCTION; ALENDRONATE; REPRODUCIBILITY; RISEDRONATE;

D O I：

10.1007/s00198-012-2093-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Guidelines concerning the definition of failure of therapies used to reduce the risk of fracture are provided. This study aims to provide guidelines concerning the definition of failure of therapies used to reduce the risk of fracture. A working group of the Committee of Scientific Advisors of the International Osteoporosis Foundation was convened to define outcome variables that may assist clinicians in decision making. In the face of limited evidence, failure of treatment may be inferred when two or more incident fractures have occurred during treatment, when serial measurements of bone remodelling markers are not suppressed by anti-resorptive therapy and where bone mineral density continues to decrease. The provision of pragmatic criteria to define failure to respond to treatment provides an unmet clinical need and may stimulate research into an important issue.

引用

页码：2769 / 2774

页数：6

共 45 条

[31] Alendronate reduces the risk of multiple symptomatic fractures: Results from the fracture intervention trial [J].